Featured Research

from universities, journals, and other organizations

Faulty Gene Linked To Prostate Cancer Risk

Date:
November 2, 2006
Source:
BMJ Specialty Journals
Summary:
Missing sections of a gene, which programs the manufacture of a chemical to alert the body to DNA damage, almost doubles the risk of prostate cancer, reveals research published ahead of print in the Journal of Medical Genetics.

Missing sections of a gene, which programmes the manufacture of a chemical to alert the body to DNA damage, almost doubles the risk of prostate cancer, reveals research published ahead of print in the Journal of Medical Genetics.

The researchers assessed almost 2,000 Polish men who had been diagnosed with prostate cancer between 1999 and 2005 to see if they carried the CHEK2 kinase gene, or CHEK2 for short.

The findings were compared with those from almost 5,500 healthy people from the general population..

The same missing sections (exons 9 and 10) were found in 24 of the healthy people (0.4%) and in 15 of the men who had been diagnosed with the disease (0.8%). They also found this deletion in four out of 249 men with familial prostate cancer.

Based on their findings, the authors calculated that this particular deletion almost doubled the risk of developing prostate cancer in general, and almost quadrupled it in men with a family history of the disease.

The authors suggest that this deletion may also be relatively common among men from other parts of eastern Europe, including the Ukraine, Belarus, Russia, the Baltic states, and countries in the Balkans.

And the findings prompt them to speculate whether the same deletion might not be carried by men elsewhere in the world.


Story Source:

The above story is based on materials provided by BMJ Specialty Journals. Note: Materials may be edited for content and length.


Cite This Page:

BMJ Specialty Journals. "Faulty Gene Linked To Prostate Cancer Risk." ScienceDaily. ScienceDaily, 2 November 2006. <www.sciencedaily.com/releases/2006/10/061031192339.htm>.
BMJ Specialty Journals. (2006, November 2). Faulty Gene Linked To Prostate Cancer Risk. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/10/061031192339.htm
BMJ Specialty Journals. "Faulty Gene Linked To Prostate Cancer Risk." ScienceDaily. www.sciencedaily.com/releases/2006/10/061031192339.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins